Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Apellis Pharmaceuticals (APLS) Share Price

News headlines about Apellis Pharmaceuticals (NASDAQ:APLS) have trended somewhat positive on Friday, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Apellis Pharmaceuticals earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave news coverage about the company an impact score of 47.1739917521519 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

APLS opened at $23.16 on Friday. The company has a quick ratio of 27.79, a current ratio of 27.79 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $1,198.37 and a price-to-earnings ratio of -6.31. Apellis Pharmaceuticals has a 1-year low of $12.45 and a 1-year high of $27.53.

How to Become a New Pot Stock Millionaire

A number of equities research analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Apellis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a research report on Monday. JPMorgan Chase increased their target price on shares of Apellis Pharmaceuticals from $31.00 to $35.00 and gave the stock an “overweight” rating in a research report on Friday, March 23rd. Finally, B. Riley assumed coverage on shares of Apellis Pharmaceuticals in a research report on Thursday, February 8th. They set a “buy” rating and a $27.00 target price for the company. Five investment analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus price target of $27.50.

ILLEGAL ACTIVITY NOTICE: This report was published by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.tickerreport.com/banking-finance/3334789/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-apellis-pharmaceuticals-apls-share-price.html.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.

Insider Buying and Selling by Quarter for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Intrepid Potash  Receiving Somewhat Favorable Media Coverage, Study Finds
Intrepid Potash Receiving Somewhat Favorable Media Coverage, Study Finds
SandRidge Energy  Earns Daily Coverage Optimism Score of 0.17
SandRidge Energy Earns Daily Coverage Optimism Score of 0.17
Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Westwood Holdings Group  Stock Price
Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Westwood Holdings Group Stock Price
Park-Ohio  Given Media Impact Rating of 0.08
Park-Ohio Given Media Impact Rating of 0.08
L Brands Same-Store Sales Grow 4% in March, Stock Climbs by 0%
L Brands Same-Store Sales Grow 4% in March, Stock Climbs by 0%
Hilton Worldwide  Sees Large Volume Increase
Hilton Worldwide Sees Large Volume Increase


Leave a Reply

© 2006-2018 Ticker Report. Google+.